Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
Silo Pharma commends recent U.S. federal actions accelerating development and regulatory clarity for psychedelic-based therapies addressing PTSD and related mental health disorders, highlighting its own PTSD-focused drug candidate SPC-15. The FDA's investigational new drug clearance for noribogaine and upcoming psychedelic drug development guidance…
